oxazoles has been researched along with Airflow Obstruction, Chronic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cahn, A; Fahy, WA; Hessel, EM; Homayoun-Valiani, F; Lowings, M; Marotti, M; Meeraus, WH; Robertson, J; Tabberer, M; Templeton, A; West, SL; Wilson, R | 1 |
| Begg, M; Cahn, A; Dunsire, L; Fuhr, R; Galinanes-Garcia, L; Hamblin, JN; Hessel, EM; Kirsten, AM; Leemereise, CN; Montembault, M; Sriskantharajah, S; Watz, H; Wilson, R | 1 |
| Amour, A; Baldwin, IR; Cooper, AW; Deakin, AM; Down, K; Felton, LM; Guntrip, SB; Hamblin, JN; Hardy, C; Harrison, ZA; Jones, KL; Jones, P; Keeling, SE; Le, J; Livia, S; Lucas, F; Lunniss, CJ; Parr, NJ; Robinson, E; Rowland, P; Smith, S; Thomas, DA; Vitulli, G; Washio, Y | 1 |
2 trial(s) available for oxazoles and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study.
Topics: Bronchodilator Agents; Double-Blind Method; Forced Expiratory Volume; Humans; Indazoles; Indoles; Oxazoles; Phosphatidylinositol 3-Kinases; Piperazines; Pulmonary Disease, Chronic Obstructive | 2021 |
Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD.
Topics: Administration, Inhalation; Aged; Class I Phosphatidylinositol 3-Kinases; Cytokines; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Indazoles; Indoles; Male; Middle Aged; Oxazoles; Piperazines; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Sputum; Treatment Outcome | 2017 |
1 other study(ies) available for oxazoles and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease.
Topics: Administration, Inhalation; Animals; Asthma; Female; Humans; Indazoles; Indoles; Isoenzymes; Male; Microsomes; Molecular Docking Simulation; Ovalbumin; Oxazoles; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Pneumonia; Pulmonary Disease, Chronic Obstructive; Rabbits; Rats; Rats, Sprague-Dawley; Respiratory Tract Diseases; Stereoisomerism; Structure-Activity Relationship; Sulfonamides; Th2 Cells | 2015 |